WO2004069217A1 - Composition cosmetique a base de cirsimarine - Google Patents
Composition cosmetique a base de cirsimarine Download PDFInfo
- Publication number
- WO2004069217A1 WO2004069217A1 PCT/FR2003/003938 FR0303938W WO2004069217A1 WO 2004069217 A1 WO2004069217 A1 WO 2004069217A1 FR 0303938 W FR0303938 W FR 0303938W WO 2004069217 A1 WO2004069217 A1 WO 2004069217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cosmetic composition
- composition according
- extract
- molecule
- cirsimarine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Definitions
- the invention relates to a cosmetic composition based on cirsimarine or cirsimarine derivatives, intended in particular for the cosmetic treatment of cellulite.
- Adipose tissue is made up of cells called adipocytes, most of whose cell space is occupied by triglycerides.
- the amount of triglycerides in an organism depends on both the size and the number of fat cells.
- hypertrophy of fat cells increase in size
- hyperplasia of these cells increase in number
- hypertrophy and hyperplasia of adipose cells are closely linked mechanisms. It has been shown that the increase in the number of adipocytes is first preceded by an increase in the size of the adipocytes up to a critical threshold, which triggers the recruitment of new adipose cells.
- the control of the only size parameter is sufficient.
- the subcutaneous adipocytes are located in fatty chambers delimited by connective tissue.
- the fatty chambers are deformed and tensions are exerted on the connective tissue delimiting them. These tensions make appear, on the surface of the skin, a wrinkling in appearance of orange peel characteristic of cellulite.
- a solution to treat the phenomenon of cellulite is to reduce the size of the adipocytes. To do this, it is necessary to catabolize, that is to say to degrade, the triglycerides contained in the adipocytes, phenomenon called "lipolysis".
- the main lipolytic agents present in the organism are neurotransmitters of the catecholamine type, respectively adrenaline and noradrenaline, neuro-transmitters of the sympathetic nervous system. These catecholamines act on several types of receptors, essentially the ⁇ -adrenergic receptors and the ⁇ -adrenergic receptors present in the extracellular medium on the surface of the adipocyte membrane.
- Adenylate cyclase plays an important role in the regulation of lipolysis. When activated, adenylate cyclase degrades adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), which then transforms an inactive protein kinase A into active phosphorylated protein A, hydrolyzing triglycerides to di, then mono glycerides.
- ATP adenosine triphosphate
- cAMP cyclic adenosine monophosphate
- the higher the intracellular concentration of cAMP the more active the lipolysis. This therefore means that to stimulate lipolysis, it is necessary to increase the intracellular concentration of cAMP. However, this concentration is subject to several regulations.
- cAMP is permanently degraded by a phosphodiesterase activated by insulin (anti-lipolytic agent) into 5'-AMP, which in turn is degraded to adenosine.
- adenosine can leave the cell towards the extracellular medium where it binds to membrane type A adenosine receptors, which are themselves coupled to adenylate cyclase via the inhibitory protein G.
- adenosine has an inhibitory effect on the activity of adenylate cyclase, and therefore of lipolysis. So that means that lipolysis is permanently inhibited and that when you stimulate lipolysis with stimulants, you are actually stimulating a system that is permanently inhibited.
- the Applicant's idea is not to directly stimulate lipolysis, but to lift the permanent inhibition which is exerted on lipolysis by blocking the adenosine A1 receptors, present on the surface of adipocytes.
- Caffeine and theophylline are molecules reported to be adenosine A1 receptor antagonists, caffeine being known for its lipolytic activity.
- the difficulty faced by the Applicant is that all the molecules having antagonist properties of the A1 receptors do not have a lipolytic activity such that one can envisage a cosmetic application.
- This is demonstrated by the documents NOGOWSKI "Genistein-Induced Changes in lipid metabolism of ovariectomized rats", Armais of Nutrition and Metabolism, 42 (1-2): 360-366 and JACOBSON "Interactions offlavones and other phytochemicals with adenosine receptors", Adv. Exp. Med. Biol., 505: 163-171, in which it is stated that genistein, a molecule belonging to the flavonoid family, identified as an Al receptor antagonist, had negligible lipolytic activity.
- the problem which the invention proposes to solve is to search for a molecule antagonist of the A1 receptors which has an improved lipolytic effect compared to known molecules, such as in particular caffeine.
- Cirsimarine is a flavonoid belonging to the class of flavones. It is a glycosilated flavone whose crude formula is C 23 H 24 0n corresponding to the CAS number 13020-19-04. It is also known under the names:
- Cirsimarine is found naturally in a very limited number of plants. They are found in particular in Teucrium arduini (family Lamiaceae), Clerodendrum mandarinorum (family Verbenaceae), Scoparia dulcis (family Scrophulariaceae), Cirsium maritimum (family Compositae) and Cirsium pendulum.
- a more widespread plant in which we find cirsimarine is a creeping herb called Microtea debilis belonging to the family of Phytolaccaceae, an annual herb native to South America. This herb is known for its use in traditional medicine in the form of dried plant powder, administered orally to treat proteinuria.
- the Applicant has demonstrated this property, the probable mechanism of action of cirsimarine corresponding to the blocking of Al receptors, present on the surface of adipocytes.
- the radical R is a hydrogen atom
- the molecule used in the invention corresponds to cirsimaritine. This molecule is known by the following names:
- Cirsimaritine is reported in many cultivated plants such as Salvia tomentosa (family Lamiaceae), Salvia officinalis, Lippia citriodora (family Verbenaceae), but also in the wild in Sideretis sventenii (family Lamiaceae), Ocimum gratissimum, variety gratissimum (Lamiaceae family), this list is not exhaustive.
- the invention relates to the use of the molecule of the following formula:
- the activation of lipolysis would not be exerted by the direct stimulation of lipolysis, but by lifting the permanent inhibition exerted on lipolysis by blocking the Al receptors present on the surface of adipocytes.
- This use can be therapeutic or non-therapeutic.
- the invention therefore relates to the use of the above-mentioned molecule in a cosmetic composition intended for the topical treatment of cellulite.
- the Applicant has moreover found that the aforementioned molecule stimulates the synthesis of the components of the extracellular matrix. More precisely, it increases the synthesis of structural proteins (collagen, elastin), the synthesis of adhesion molecules (collagen, laminin, nidogen, integrin, cadherin, ...) as well as the synthesis of polysaccharides (glycosaminoglycans and proteogly canes) .
- the invention therefore also relates to the use of the aforementioned molecule for the manufacture of a composition intended to stimulate the synthesis of the components of the extracellular matrix.
- compositions comprising as active ingredient, cirsimarine or cirsimaritine corresponding to the formulas mentioned above.
- the concentration of cirsimarine or cirsimaritine in the cosmetic composition is between 0.0005 and 10% by weight, advantageously between 0.05 and 5% by weight.
- cirsimarine is in the form of a dry or liquid plant extract, preferably from Microtea debilis.
- the extract When the extract is in dry form, it represents between 0.005 and 20%, advantageously between 0.1 and 10% by weight of the composition.
- the extract When the extract is in liquid form, it represents between 0.1 and 20%, advantageously between 0.5 and 10% by weight of the composition.
- the extraction is carried out from the whole plant, dried and then ground, in a polar solvent which can be used in a topical cosmetic application, therefore in aqueous, alcoholic or glycolic media.
- the polar solvent is chosen from the group comprising water, ethanol, glycols such as propylene glycol, butylene glycol, alone or as a mixture, ethanol however remaining one of the preferred solvents.
- the Applicant has moreover demonstrated the existence of a synergy between cirsimarine or cirsimaritine and xanthic bases, such as for example caffeine, on lipolysis.
- the cosmetic composition of the invention therefore also contains a xanthic base, in particular caffeine.
- caffeine represents between 0.1 and 10% of the composition, by weight.
- composition will also be generally formulated in the form, for example, of gel, milk, cream, serum, microemulsion, etc.
- composition according to the invention can be in all the galenical forms normally used for topical application to the skin or the hair, in particular in the form of an aqueous solution, of an oil-in-water or water-in- emulsion. oil or multiple, of a silicone emulsion, of a microemulsion or nanoemulsion, of an aqueous gel.
- composition can be more or less fluid and have the appearance of, among other things, a white or colored cream, an ointment, a milk, a lotion, a serum, a gel.
- the composition of the invention may contain the adjuvants usual in the cosmetic and dermatological fields, such as fats, emulsifiers and co-emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, hydrophilic and lipophilic filters, dyes, neutralizers, penetrating agents, and polymers.
- these various adjuvants are those conventionally used in the fields considered, and for example from 0.01 to 30% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase or into the aqueous phase.
- mineral oils oils of animal origin (lanolin)
- synthetic oils isopropyl myristate, octyldodecyl, isostearyl isostearate, decyl oleate, isopropyl palmitate
- silicone oils cyclomethicone, dimethicone
- Fatty alcohols, fatty acids, waxes and gums and in particular gums and silicone elastomers can be used as fats.
- emulsifiers and coemulsifiers which can be used in the invention, mention may, for example, be made of polyglycerol and fatty acid esters, sucrose and fatty acid esters, sorbitan and fatty acid esters, acid esters fatty and sorbitan oxyethylenated, ethers of fatty alcohol and PEG, esters of glycerol and fatty acid, all yl sulfates, alkyl ether sulfates, alkyl phosphates, alkyl polyglucosides, dimethicone copolyols.
- hydrophilic gelling agents there may be mentioned in particular include carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate, the polyacrylamid 'es, polysaccharides such as xanthan gum, guar gum, natural gums such than cellulose gum and derivatives, clays and copolymers of 2-acrylamido-2-methyl lpropane acid.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkylacrylate
- polysaccharides such as xanthan gum, guar gum
- natural gums such than cellulose gum and derivatives
- clays and copolymers of 2-acrylamido-2-methyl lpropane acid As lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and ethylcellulose.
- the cosmetic composition can also contain active ingredients.
- active agents depigmentants, emollients, moisturizers, antiseborrheics, anti-acne, keratolytic and / or desquamating agents, anti-wrinkle and tightening agents, draining agents, anti-irritants, can be used in particular.
- soothing agents slimming agents such as xanthic bases (caffeine), vitamins and their mixtures, and matting agents.
- the active agents indicated above and / or the extract of Microtea debilis can be incorporated into spherules, in particular ionic or nonionic vesicles and / or nanoparticles (nanocapsules and / or nanospheres), so as to isolate them from each other in the composition.
- preservatives which can be used according to the invention, mention may be made of benzoic acid, its salts and its esters; sorbic acid and its salts; parabens, their salts and esters; triclosan; imidazolidinyl urea; phenoxyethanol; DMDM hydantoin; diazolidinyl urea; chlorphenesin.
- antioxidants which can be used according to the invention, mention may be made of chelating agents such as EDTA and its salts.
- UVA and UVB filters conventionally used such as benzophenone-3, butyl methoxydibenzoyl methane, octocrylene, octyl methoxycinnamate, 4-methylbenzylidene camphor, octyl salycylate, tacephthalylidene dicamphor sulfanic acid, and drometrizole trisiloxane. Mention will also be made of physical filters TiO 2 and ZnO in their micrometric and nanometric forms.
- coloring materials which can be used according to the invention, mention may be made of lipophilic dyes, hydrophilic dyes, pigments and nacres usually used in cosmetic or dermatological compositions, and their mixtures.
- neutralizers which can be used according to the invention, mention may be made of sodium hydroxide, triethanolamine, aminomethyl propanol and potassium hydroxide.
- penetrating agents which can be used according to the invention, there may be mentioned alcohols and glycols (ethanol, propylene glycol), ethoxydiglycol, alcohols and fatty acids (oleic acid), fatty acid esters, dimethyl isosorbide.
- composition according to the invention can be used as a care product (for example a slimming product), as a cleansing product, and / or as a skin makeup product, as a sun protection product, or as a hair product, for example as a shampoo or after shampoo.
- a care product for example a slimming product
- a cleansing product for example a soap, a soap, and / or as a skin makeup product, as a sun protection product, or as a hair product, for example as a shampoo or after shampoo.
- the invention also relates to a cosmetic treatment method for cellulite, comprising locally applying an effective amount of the cosmetic composition topically.
- Figure 1 is a diagram illustrating the regulation of lipolysis in adipocytes.
- FIG. 2 represents the lipolytic activity of cirsimarine compared to control molecules (caffeine, theophylline, noradrenaline).
- FIG. 3 represents the lipolytic activity of the cirsimarine / caffeine association with respect to caffeine alone.
- Example 1 making an extract of Microtea debilis
- the whole dried plant comes from South America. This plant is ground until a powder is obtained.
- the extraction of the crushed plant is carried out in an ethanol mixture 96.2 ° H 2 0 (80/20); volume / volume at room temperature with magnetic stirring, protected from light, for 6 hours.
- the extract is then filtered on a nylon filter and then on a cellulose membrane (up to 0.22 microns).
- Noradrenaline (syn. Norepinephrine NE): this molecule, of molar mass 319.3 g, is evaluated at the final concentration of 1 ⁇ M in KREBS-RINGER buffer at 4% albumin.”
- Caffeine this molecule, of mass 194.2 g molar, is evaluated at the final concentration of 0.5 mM in KREBS-RINGER buffer at 4% albumin.
- Theophylline this molecule with a molar mass of 180.2 is evaluated at the final concentration of 0.5 mM in KREBS-RINGER buffer at 4% albumin.
- Cirsimarine this molecule of molar mass 476.44 is tested at 0.5 mM and 0.1 lmM. This molecule is first of all dissolved in a mixture of solvents: 0.2 M NaOH / DMSO (95/5; v / v).
- the defatted albumin will fix the fatty acids released during lipolysis; this precaution is important because they retio-inhibit lipolysis.
- the buffer solution is brought to 37 ° C.
- the epididymal adipose tissue is removed from rats. It is placed in KREBS-RINGER bicarbonate buffer at 4% albumin and at pH 7.4, to which 188 units of collagenase / ml will have been added to digest the collagen network which supports the adipose tissue.
- the digestion lasts about one hour at 37 ° C with stirring. It is stopped by strongly diluting the collagenase by successive rinses of the adipocyte suspension with KREBS-RINGER buffer at 4% albumin.
- the reaction tubes used are 2 mL EPPENDORF ® tubes. If A is the volume in ⁇ L of adipocyte solution necessary to have the concentration of 150,000 cells / ml and B the volume in ⁇ L of mother solution of the molecule to be tested, we first put in the EPPENDORF® tube (1 000-AB) ⁇ L of KREBS-RINGER buffer at 4% albumin, then the B ⁇ L of stock solution of the molecule to be tested. The volume of the tube is then made up to 1 ml by delicately depositing on the surface the volume necessary for the solution of adipocytes A.
- control tubes are produced.
- Eight 2mL EPPENDORF tubes are prepared with A ⁇ L of adipocyte solution and (1000-A) ⁇ L of KREBS-RINGER buffer; four tubes are prepared with A ⁇ L of adipocyte solution, B ⁇ L of solvent for dissolving cirsimarine and (1,000-A-B) ⁇ L of KREBS-RINGER buffer.
- Lipolytic activity is measured by the amount of free fatty acids; a NEFA C colorimetric assay kit (Non Esterified Fatty Acid / Colorimetric) sold by WAKO Chemical GmbH is used for this. 2.2 / Results
- the amount of free fatty acids present in tubes 0 minus that present in tubes 00 corresponds to the basal lipolysis of the adipocytes in the buffer.
- the quantity of free fatty acids present in the tubes 0 solvent minus that present in the tubes 00 corresponds to the basal lipolysis of the adipocytes in the buffer containing the solvent for dissolving cirsimarine.
- the quantity of fatty acids released in the reaction tubes minus that present in the 00 tubes corresponds to the lipolysis induced by the molecules studied. The results appear in Figure 2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002512275A CA2512275A1 (fr) | 2003-01-09 | 2003-12-30 | Composition cosmetique a base de cirsimarine |
US10/541,646 US20060115502A1 (en) | 2003-01-09 | 2003-12-30 | Cosmetic composition based on cirsimarin |
BR0317925-7A BR0317925A (pt) | 2003-01-09 | 2003-12-30 | Utilização de uma molécula ativa, composição cosmética e processo de tratamento da celulite |
AU2003303900A AU2003303900A1 (en) | 2003-01-09 | 2003-12-30 | Cosmetic composition based on cirsimarin |
EP03815708A EP1581178A1 (fr) | 2003-01-09 | 2003-12-30 | Composition cosmétique a base de cirsimarine |
JP2004567801A JP2006514082A (ja) | 2003-01-09 | 2003-12-30 | キルシマリンをベースにした化粧品組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR03/00197 | 2003-01-09 | ||
FR0300197A FR2849775B1 (fr) | 2003-01-09 | 2003-01-09 | Composition cosmetique a base de cirsimarine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004069217A1 true WO2004069217A1 (fr) | 2004-08-19 |
Family
ID=32524787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/003938 WO2004069217A1 (fr) | 2003-01-09 | 2003-12-30 | Composition cosmetique a base de cirsimarine |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060115502A1 (fr) |
EP (1) | EP1581178A1 (fr) |
JP (1) | JP2006514082A (fr) |
AU (1) | AU2003303900A1 (fr) |
BR (1) | BR0317925A (fr) |
CA (1) | CA2512275A1 (fr) |
FR (1) | FR2849775B1 (fr) |
WO (1) | WO2004069217A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009156482A1 (fr) | 2008-06-26 | 2009-12-30 | Biofarma Spa | Composition cosmétique, utilisation et procédé de production associé |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1970051A1 (fr) * | 2007-03-14 | 2008-09-17 | Merz Pharma GmbH & Co.KGaA | Utilisation d'une micro-émulsion aqueuse pour la préparation d'une formulation pour le traitement de maladies adipeuses |
JP2011148708A (ja) * | 2010-01-19 | 2011-08-04 | Noevir Co Ltd | 保湿剤、抗老化剤、抗酸化剤、痩身剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤及び機能性経口組成物 |
US10039709B2 (en) * | 2010-06-04 | 2018-08-07 | Trilogic Pharma Llc | Bioadhesive compositions for epithelial drug delivery |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2233071A1 (en) * | 1973-06-14 | 1975-01-10 | Prod Hyg Laboratoires | Flavones and saponins extracted from ivy - by solid-liquid extraction of undesirables followed by alcohol extraction |
EP0418806A1 (fr) * | 1989-09-21 | 1991-03-27 | INDENA S.p.A. | Compositions pharmaceutiques ayant un effet sur la microcirculation cutanéenne |
FR2742055A1 (fr) * | 1995-12-12 | 1997-06-13 | Ennagram | Melange d'extraits de plantes et leurs utilisations, notamment pour le traitement local symptomatique des surcharges adipeuses sous-cutanees localisees |
FR2778663A1 (fr) * | 1998-05-15 | 1999-11-19 | Coletica | Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire |
WO2001024808A1 (fr) * | 1999-10-06 | 2001-04-12 | Bioactiva Microtechne | Produits a base de canelo et leurs procedes de fabrication et d'application |
US20020106388A1 (en) * | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
US6451837B1 (en) * | 1999-09-01 | 2002-09-17 | Andrius Baskys | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors |
US20020160064A1 (en) * | 2001-02-26 | 2002-10-31 | Fred Zulli | Cosmetics containing isoflavone aglycones |
-
2003
- 2003-01-09 FR FR0300197A patent/FR2849775B1/fr not_active Expired - Fee Related
- 2003-12-30 CA CA002512275A patent/CA2512275A1/fr not_active Abandoned
- 2003-12-30 US US10/541,646 patent/US20060115502A1/en not_active Abandoned
- 2003-12-30 EP EP03815708A patent/EP1581178A1/fr not_active Withdrawn
- 2003-12-30 JP JP2004567801A patent/JP2006514082A/ja active Pending
- 2003-12-30 AU AU2003303900A patent/AU2003303900A1/en not_active Abandoned
- 2003-12-30 WO PCT/FR2003/003938 patent/WO2004069217A1/fr not_active Application Discontinuation
- 2003-12-30 BR BR0317925-7A patent/BR0317925A/pt not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2233071A1 (en) * | 1973-06-14 | 1975-01-10 | Prod Hyg Laboratoires | Flavones and saponins extracted from ivy - by solid-liquid extraction of undesirables followed by alcohol extraction |
EP0418806A1 (fr) * | 1989-09-21 | 1991-03-27 | INDENA S.p.A. | Compositions pharmaceutiques ayant un effet sur la microcirculation cutanéenne |
FR2742055A1 (fr) * | 1995-12-12 | 1997-06-13 | Ennagram | Melange d'extraits de plantes et leurs utilisations, notamment pour le traitement local symptomatique des surcharges adipeuses sous-cutanees localisees |
FR2778663A1 (fr) * | 1998-05-15 | 1999-11-19 | Coletica | Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire |
US6451837B1 (en) * | 1999-09-01 | 2002-09-17 | Andrius Baskys | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors |
WO2001024808A1 (fr) * | 1999-10-06 | 2001-04-12 | Bioactiva Microtechne | Produits a base de canelo et leurs procedes de fabrication et d'application |
US20020106388A1 (en) * | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
US20020160064A1 (en) * | 2001-02-26 | 2002-10-31 | Fred Zulli | Cosmetics containing isoflavone aglycones |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009156482A1 (fr) | 2008-06-26 | 2009-12-30 | Biofarma Spa | Composition cosmétique, utilisation et procédé de production associé |
Also Published As
Publication number | Publication date |
---|---|
JP2006514082A (ja) | 2006-04-27 |
FR2849775B1 (fr) | 2005-02-11 |
AU2003303900A1 (en) | 2004-08-30 |
FR2849775A1 (fr) | 2004-07-16 |
CA2512275A1 (fr) | 2004-08-19 |
EP1581178A1 (fr) | 2005-10-05 |
BR0317925A (pt) | 2005-11-29 |
US20060115502A1 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999016415A1 (fr) | Utilisation de l'acide ellagique et de ses derives en cosmetique et en dermatologie | |
FR2918570A1 (fr) | DIGLYCATION DES AGEs. | |
EP3054963B1 (fr) | Utilisation cosmétique et/ou dermatologique d'un extrait de feuilles d'hamamelis virginiana | |
EP1231893A1 (fr) | Extrait d'ajuga turkestanica et ses applications cosmetiques | |
EP1722864A1 (fr) | Utilisation d un extrait d acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides | |
WO2020128223A1 (fr) | Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensis | |
FR3026947A1 (fr) | Activite deglycation d'une combinaison d'un extrait de salvia miltiorrhiza et de niacine et/ou de niacinamide | |
WO2014155012A9 (fr) | Utilisation cosmetique ou dermatologique d'un extrait de polygonum bistorta | |
EP0993826A1 (fr) | Utilisation d' un extrait de sanguisorba officinalis pour favoriser la pigmentation de la peau et/ou des cheveux | |
WO2013102727A1 (fr) | Extrait de graines de kniphofia uvaria, composition cosmetique ou dermatologique en contenant, et ses utilisations | |
FR2868701A1 (fr) | Composition cosmetique et/ou pharmaceutique, a action regulatrice de la proportion de graisse contenue dans les adipocytes et/ou a action regulatrice de la differenciation adipocytaire | |
FR2907338A1 (fr) | Utilisation de l'acide ferulique dans le domaine cosmetique et/ou pharmaceutique | |
WO2019069007A1 (fr) | Procédé d'utilisation d'un inhibiteur de let-7b en cosmétique et/ou en nutraceutique | |
WO2004069217A1 (fr) | Composition cosmetique a base de cirsimarine | |
EP0946140B1 (fr) | Utilisation d'un extrait de cordia dichotoma | |
EP1082097A1 (fr) | Utilisation de sophorolipides comprenant des lactones diacetylees en tant qu'agent stimulateur du metabolisme des fibroblastes de la peau | |
WO2021152250A1 (fr) | Utilisation cosmétique, nutraceutique ou dermatologique d'un extrait de tamarindus indica l. et / ou d'une composition le comprenant | |
CH694904A5 (fr) | Utilisation d'un extrait de Rhodiola crenulata, par voie topique. | |
EP3043873A1 (fr) | Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis | |
FR2985186A1 (fr) | Extrait polaire de kniphofia uvaria, composition cosmetique ou dermatologique en contenant, et ses utilisations | |
EP2590622B1 (fr) | Utilisation d'un extrait de populus balsamifera comme agent dépigmentant | |
FR3029789A1 (fr) | Utilisation d'un extrait de papaver et composition permettant cette utilisation | |
FR3097127A1 (fr) | Procédé d’utilisation d’un inhibiteur de Let-7b en cosmétique et/ou en nutraceutique | |
EP4009940A1 (fr) | Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium | |
FR3130602A1 (fr) | Composition contenant l'association d'un C-glycoside et de l'escine pour le soin du contour des yeux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003815708 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2512275 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006115502 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10541646 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004567801 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003815708 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0317925 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10541646 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003815708 Country of ref document: EP |